Society: ASGE

Background: Post-polypectomy colonoscopy surveillance can reduce the burden of colorectal cancer (CRC). However, the effectiveness of using the faecal immunochemical test (FIT) in the interval between surveillance colonoscopies for the detection of missed or rapidly progressing lesions in individuals at above-average risk of CRC, has not yet been adequately investigated. This study assessed the effectiveness of interval FIT for early detection of advanced neoplasia and the diagnostic accuracy of FIT in above-average risk people who undergo surveillance colonoscopy.

Methods: 7311 individuals from South Australia deemed to be at above-average risk of CRC due to a family history of CRC and/or a personal history of precursor lesions, and who had undergone at least 2 colonoscopy procedures were included. Individuals with a genetic syndrome, inflammatory bowel disease or previous CRC were excluded. A 2-sample FIT (OC Sensor, Eiken Chemical Company) was offered at 1-2 yearly intervals between colonoscopies, where a positive FIT result (≥20 µg Hb/g faeces) triggered an early colonoscopy from the scheduled surveillance time. FITs returned within 3 months before a complete colonoscopy were used to determine the diagnostic accuracy of FIT. Competing-risk regression was used to assess the association between interval FIT result and the risk of having advanced precursor lesions or CRC (advanced neoplasia).

Results: 9737 pairs of colonoscopies were included, with 38,424 years of total analysis time at risk. The mean (SD) age of participants was 62.7 y (±9.7) and 51% were female. Cumulative
FIT positivity was 18.1% (1388/7654). A positive FIT brought forward the time to diagnosis of cancer by 30 months (IQR: 22-38) and diagnosis of advanced precursor lesions by 20 months (IQR: 12-39). Individuals who had returned 4 consecutive negative FIT results had a significantly lower incidence of advanced neoplasia compared to individuals who did not complete a FIT (6.4% vs 10.2%, p<0.001) or individuals returning a positive FIT (6.4% vs 14.1%, p<0.001). The incidence of advanced neoplasia was lowest among those with 4 consecutive negative FIT results (subdistribution hazard ratio (SHR), 0.54; p = 0.001) and highest among those who returned 1 positive FIT (SHR, 2.62; p <0.001). Of the 689 FITs returned within 3 months prior to a complete colonoscopy, the test was positive for 4/6 cancers (sensitivity:66.7%) and 42/157 (sensitivity:26.8%) advanced precursor lesions.

Conclusion: Interval FIT enabled earlier detection of advanced neoplasia in individuals at elevated risk of CRC. Multiple rounds of negative FIT are likely to indicate a lower risk of advanced neoplasia compared to those not participating in interval FIT surveillance. The interval FIT is a significant predictor of advanced neoplasia risk and could be used as a tool to personalise surveillance colonoscopy intervals.

Background: Data about comparative effectiveness of screening with faecal immunochemical test (FIT) and with sigmoidoscopy (FS) are limited
Aims: To compare colorectal (CRC) incidence and mortality at 15-year follow-up among subjects enrolled in the FS and FIT arms in the SCORE2 (1) and SCORE 3 (2) trials.
Methods: Between November 1999 and June 2004, average risk men and women, aged 55 to 64, included in a general population sample, were enrolled in the SCORE2 and SCORE3 trials, aimed to comparative the effectiveness of different CRC screening strategies (fig.1). Invitation and examination procedures were the same in the two trials.
Only subjects randomly invited (by a personal invitation letter) to undergo FIT or FS screening are included in this analysis. Subjects with a negative FS were no longer invited, while those in the FIT arm were invited every 2 years, until age 69. The Immudia-HemSp method (Fujirebio Inc.) was used in the first two rounds of the SCORE2 and in the first round of the SCORE3 trial. All samples were processed in a centralized laboratory. The local programs subsequently adopted the OC Sensor method (Eiken co.), using 20 µg/gr. positivity cut-off. FS was performed by gastroenterologists in hospital endoscopy units. Bowel preparation was limited to a single enema self-administered at home 2 hours before the test. Colonoscopy was recommended if ≥1 polyp ≥10 mm, or ≥1 advanced adenoma, or ≥3 adenomas, or CRC was found at FS.
Follow-up was performed though automated record linkage of the trials database with the local population cancer and mortality registries. Time-to-event data were censored at time of CRC diagnosis (incidence), emigration, death, or 15 years, whichever came first. Outcome measures were CRC incidence and mortality. Adjusted hazard ratios (HR) were estimated using Cox proportional hazard models lumping the groups from the two trials. Individual patient data metanalysis is also planned.
Results: Overall, 23896 subjects were randomized to FS and 11236 to FIT screening. Participation in the initial round was 29% and 32% for FIT and 28% and 32% for FS in the SCORE2 and SCORE3 trials. During the 15-year follow-up at least 1 FIT was performed by 48% of subjects in the FIT arm performed at least 1 FIT (average FIT number=3) and by 46% of responders and 19% of non-responders in the FS arm. CRC incidence was reduced by 15% (HR: 0.85; 95%CI: 0.73-0.99) and mortality was reduced by 17% (HR:0.83; 95%CI:0.59-1.17) in the FS as compared to the FIT arm (fig.2).
Conclusions: CRC incidence was significantly reduced among subjects undergoing FS as compared to those undergoing FIT screening; the CRC mortality reduction did not reach the level of statistical significance. Participation in the FIT arms was lower than in many currently ongoing programs.
1) Segnan et al JNCI 2005 97(5)
2) Segnan et al. Gastroenterology 2007 131(7)

Background: Adenoma detection rate (ADR) is considered the single most important quality measure in colonoscopy. Endocuff-vision is a new generation of single-use, plastic device, mounted on the distal tip of the colonoscope and may potentially improve the visualization of the polyps located behind folds and flexures. However, the performance of Endocuff-vision assisted colonoscopy in Asian endoscopists had never been evaluated.

Method: Patients underwent sedative colonoscopy performed by 13 endoscopists (7 young and 6 seniors [>10 years experiences]) for either symptoms or screening or surveillance were consecutively enrolled between December 2019 and June 2020 and allocated to receive Endocuff-assisted or standard colonoscopy in block randomization. Patients who took antiplatelet, anticoagulants; having history of colectomy or inflammatory bowel disease; poor colon preparation or scheduled for endoscopic treatment were excluded. Primary outcome of study was ADR; Secondary outcomes included polyp detection rate (PDR), advanced ADR, adenomas per colonoscopy (APC), sessile serrated lesion detection rate (SDR), cecal intubation time, withdrawal time and adverse events.

Results: A total of 1,212 patients were screened for eligibility and finally 1,016 patients (median age of 56 years, 47.3% male) were included for analysis. Among them, a total of 553 patients (54.4%) received endocuff-assisted and 463 standard colonoscopies. The ADR (39.2% vs. 32.2%; P = 0.02), PDR (55.5% vs. 47.1%; P = 0.007) and APC (0.8 ± 1.3 vs. 0.6 ± 1.1; P =0.029) were significantly higher in the endocuff group than those in the standard group (Table 1). Endocoff was associated with a shorter cecal intubation time (4.2 ± 3.8 vs. 4.9 ± 4.0 minutes; P = 0.004). The differences in ADR (37.3% vs. 27.5%; P = 0.036) and cecal intubation time (5.0 ± 3.3 vs. 6.5 ± 4.6 minutes; P < 0.001) were larger, when performed by young endoscopists (Table 2). Minor mucosal laceration was found in 3 patients, and no serious adverse events reported.

Conclusion: New-generation Endocuff-assisted colonoscopy may not only improve the ADR, PDR and APC, but also shorten the cecal intubation time, especially in young endoscopists. Endocuff-vision can be routinely used to improve the quality and performance of colonoscopy.

Background and Aims:
Increasing adenoma detection rate (ADR) could be beneficial in reducing the risk of post-colonoscopy colorectal cancer. Texture and Color Enhancement Imaging (TXI) and Endocuff Vision (ECV) are found to improve ADR. TXI improves polyp detection by enhancing endoscopic images’ brightness and color contrast while maintaining color appearance close to white light imaging. Due to our impressive experience with TXI and the current evidence, our center uses TXI during inspection as a standard. Endocuff Vision (ECV) is a mucosal exposure device that helps flatten the colonic folds and increases ADR. The combined benefit of TXI and ECV have not been studied before; thus, this study aimed to compare the ADR between the combined TXI with ECV and TXI alone.

Methods:
We conducted a prospective randomized controlled trial recruiting patients age ≥40 years who undergo colonoscopy for colorectal cancer screening or any gastrointestinal symptoms. The participants were enrolled and randomized in a 1:1 ratio into TXI with ECV group (TXI+ECV group) and TXI group. Experienced endoscopists with ≥40% ADR performed all colonoscopies. Data on baseline characteristics, bowel preparation quality, intubation time, withdrawal time, and polyp characteristics were collected. Primary outcome was ADR. Secondary outcomes were adenoma per colonoscopy (APC), serrated lesion detection rate (SLDR), insertion time, and withdrawal time.

Results:
Four hundred patients were included in this study. Nineteen patients were excluded after randomization due to poor bowel preparation, colorectal cancer, colonic stricture, and failure to reach the cecum. Finally, there were 189 patients in the TXI+ECV group and 192 in the TXI group (Figure 1). Baseline characteristics between the two groups were comparable. The ADR was significantly higher in the TXI+ECV group than in the TXI group (65.6% vs. 52.1%, p=0.007). The APC was significantly greater in the TXI+ECV group than in the TXI group (1.6 vs. 1.2, p=0.021), prominently proximal (1.0 vs. 0.7, p=0.031), non-pedunculated (1.4 vs. 1.1, p=0.035), and diminutive (1.3 vs. 1, p=0.045) adenomas (Table 1). The SLDR, insertion time, and withdrawal time were not different between the two groups.

Conclusions:
Our study found that adding ECV to TXI significantly improves ADR and APC compared with TXI alone.

Trial registration: Thai Clinical Trials Registry TCTR20220507004

Sukit Pattarajierapan

Appearances